George Peter Zavitsanos, MD | |
467 Pennsylvania Ave, Suite 203, Fort Washington, PA 19034-3420 | |
(215) 641-2300 | |
(215) 628-2411 |
Full Name | George Peter Zavitsanos |
---|---|
Gender | Male |
Speciality | Plastic And Reconstructive Surgery |
Experience | 36 Years |
Location | 467 Pennsylvania Ave, Fort Washington, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1740289008 | NPI | - | NPPES |
0017043800002 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2082S0105X | Plastic Surgery - Surgery Of The Hand | MD042591L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
George Peter Zavitsanos, MD 467 Pennsylvania Ave, Suite 203, Fort Washington, PA 19034-3420 Ph: (215) 641-2300 | George Peter Zavitsanos, MD 467 Pennsylvania Ave, Suite 203, Fort Washington, PA 19034-3420 Ph: (215) 641-2300 |
News Archive
Warner Chilcott plc today announced that its subsidiaries, Warner Chilcott Company, LLC and Warner Chilcott Finance LLC (together, the "Issuers"), plan to issue an aggregate principal amount of $500 million of 7-3/4% senior notes due 2018 (the "Notes") in a private placement. The notes are additional notes constituting a part of the same series as the $750 million aggregate principal amount of 7-3/4% senior notes due 2018 issued on August 20, 2010.
Bladder cancer is associated with significant illness and mortality, particularly if treatment is delayed.
Celsion Corporation today announced that Dr. Thanjavur S. Ravikumar, from the Geisinger Health System and a principal investigator of the Phase I ThermoDox® dose escalation trial, gave an oral presentation at the Liver Tumors Panel session of the 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA) in Buenos Aires, Argentina.
The last decade has seen a strong movement towards the use of various quality measurements to grade medical care. In surgery, 30-day mortality is one of the most common benchmarks. We wanted to determine if patterns of postoperative mortality showed any signs that the process of measuring medical care might actually alter how (and when) care is provided or withdrawn.
In a major step that could revolutionize biomedical research, scientists have discovered a way to keep normal cells as well as tumor cells taken from an individual cancer patient alive in the laboratory - which previously had not been possible. Normal cells usually die in the lab after dividing only a few times, and many common cancers will not grow, unaltered, outside of the body.
› Verified 5 days ago